Business growth

North America Non-Oncology Biopharmaceuticals Market to Future Business Growth 2018-2026 | Sanofi SA, Pfizer, Novartis International AG, Amgen

Biopharmaceuticals are high molecular weight proteins and peptides that are generated or synthesized from living biological sources. Biologics and biosimilars are two types of biopharmaceuticals. Biologics are compounds derived from living cells such as microbes, plant or animal cells, and used in the treatment, diagnosis or prevention of disease. The majority of biological molecules are extremely massive and complex compounds or mixtures of molecules. The FDA defines a biosimilar as a biological product that is highly comparable to an existing FDA-approved reference product and has no clinically relevant changes.

The US non-oncology biopharmaceuticals market size was valued at US$ 116.0 billion in 2018 and is expected to grow at a CAGR of 10.2% during the forecast period (2018-2026).

Request more information about this report (including full TOC, table and figures)

Non-oncology biopharmaceuticals are drugs used to treat conditions other than cancer, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis and others.

The following key players are mentioned in this document:

US Non-Oncology Biopharmaceuticals Market: Segmentation

By product type:

By drug class:

    • Monoclonal antibody
    • Enzyme replacement therapy
    • Erythropoietin
    • Interferon
    • white blood cell growth factor
    • Botulinum toxin
    • Fusion Protein
    • Vaccines
    • Recombinant Human Insulin
    • Blood factors
    • human growth hormone
    • Others

By disease indication:

    • Diabetes
    • rheumatoid arthritis
    • Psoriatic arthritis
    • Multiple sclerosis
    • Haemophilia
    • Anemia
    • Macular degeneration
    • Hepatitis B
    • Cystic fibrosis
    • Osteoporosis
    • Crohn’s disease
    • Ulcerative colitis
    • Psoriasis
    • Ankylosing spondylitis
    • Others (heart and other diseases)

Click on the link to the PDF brochure with the latest information

In this segment, we will give you the impact of COVID-19, how it has affected the US non-oncology biopharmaceuticals market and how it will change the future of the industry based on the current government, private and public situations. Our expert analysts keep an eye out for any situations that could alter the flow of the industry, helping you make the best possible decision for your business.

The objective of the study is to define the US Non-Oncology Biopharmaceuticals market size of different segments and countries in previous years and to forecast the values ​​to the next Five years. The report is designed to incorporate qualified qualitative and quantitative aspects of the industry with respect to each region and country involved in the study. Furthermore, the report also provides detailed information about crucial aspects such as drivers and restraining factors which will define the future growth of the US Non-Oncology Biopharmaceuticals market.

Key benefits of the report:

  • This study presents the analytical description of the global Non-Oncology Biopharmaceuticals industry in the United States together with the current trends and future estimations to determine the impending pockets of investment.
  • The report presents information related to key drivers, restraints, and opportunities, along with a detailed analysis of the global non-oncology biopharmaceuticals market share in the United States.
  • The current market is quantitatively analyzed from 2018 to 2026 to highlight the growth scenario of the global Non-Oncology Biopharmaceuticals market in the US.
  • Porter’s five forces analysis illustrates the power of buyers and sellers in the market.
  • The report provides a detailed analysis of the Global US Non-Oncology Biopharmaceuticals Market based on the competitive intensity and how the competition will shape in the coming years.

Main points covered in the table of contents:

Market summary: It includes six sections, research scope, key players covered, market segments by type, US Non-Oncology Biopharmaceuticals market segments by application, study objectives and years considered.

Market landscape: Here, the global non-oncology biopharmaceuticals market in the United States is dissected, by value, revenue, volume, market rate and latest patterns. The development and consolidation of the entire industry and major organizations are provided by charts and a slice of the cake for organizations.

Company profiles: Here, leading players of the global US Non-Oncology Biopharmaceuticals market are considered based on sales in regions, key innovations, net income, cost, and other factors.

Market Status and Outlook by Region: In this segment, the report examines net transactions, revenue, creation and global industry share, CAGR and market size by region. Global Non-Oncology Biopharmaceuticals Market in United States is thoroughly examined based on regions and countries like North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Sector analysis: Accurate and reliable forecasts on the market share of essential sections of the US non-oncology biopharmaceuticals market are provided

Market Forecast: In this section, accurate and validated values ​​of the total market size in terms of value and volume are provided by the research analysts. Additionally, the report includes production, consumption, sales, and other forecasts for the global non-oncology biopharmaceuticals market in the United States.

Market trends: An in-depth analysis of recent and future market trends is provided in this section.

Survey before buying this premium report

About Us:

Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We are known for our actionable insights and genuine reports in various fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insights in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

contact us